Ajanta Pharma receives US FDA nod for migraine drug zolmitriptan

Ajanta Pharma Limited has received final approval for zolmitriptan tablet (2.5 mg and 5 mg) from the US Food and Drug Administration (FDA). Zolmitriptan tablet is used in the acute treatment of migraine and is a bioequivalent generic version of Zomig, a registered trademark of AstraZeneca.
 
Zolmitriptan tablet is part of an ever-growing portfolio of products that Ajanta has developed for the US market. To date, the US FDA has granted Ajanta Pharma nine ANDA final approvals and two tentative approvals. Additional 15 ANDAs are under review with the FDA.